CClinicalTrials.gg
RecruitingNCT06409806EMBRIUpdated Sep 19, 2024

Electrocorticographic Monitoring of Brain Retraction Injury (EMBRI)

An interventional study of ECOG Array in Brain Injury, Neurosurgery and Brain Ischemia, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University College, London · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Study summary

A single centre IDEAL Stage 1 feasibility study using novel electrophysiological recording techniques in adult participants undergoing neurosurgery. This is a first in human study, building upon previous preclinical mice experiments.

Participants will undergo their planned neurosurgical procedure as normal. In addition to their standard treatment neurophysiological monitoring including an electrocorticography electrode placed on the brain deep to the retractor will be used to monitor for signs of brain retraction injury.

02

Conditions studied

  • Brain Injury
  • Neurosurgery
  • Brain Ischemia

Keywords

  • Brain retraction
03

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 16 or older undergoing intracranial surgery where it is anticipated fixed brain retraction will be used.

Exclusion criteria

Exclusion Criteria:

  • Patients without capacity to give consent at time of recruitment
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Other: ECOG Array

Interventions

  • OtherECOG Array

    The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment. Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference. Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain.

05

What researchers measure

Primary outcomes

  1. Evaluate the feasibility of integrating the ECoG brain retractor into standard traditional neurosurgical operative workflow.

    The primary outcome is to report the feasibility of integrating the ECoG brain retractor into standard traditional neurosurgical operative workflow based upon analysing prospective data including qualitative questionnaires administered to surgeons and scrub nurses, anonymised clinical data, and anonymised electrophysiological data. The primary outcome is to produce a descriptive report of the electrophysiological data recorded and the challenges encountered in the delivery of the novel electrophysiological recording for patients undergoing planned neurosurgical procedures at the National Hospital for Neurology and Neurosurgery, London.

    Time frame: Over a 28 month period from November 2022 to March 2026

Secondary outcomes

  1. Analyse the captured electrophysiological data to investigate any correlation between the electrophysiological signature and duration of retraction.

    The secondary objective is to analyse the captured electrophysiological data to investigate any correlation between the electrophysiological signature and duration of retraction. Post-operative clinical data, such as MRI brain scans, can be reviewed to investigate any ischemic events. We will perform an initial analysis of the electrophysiological data to see if neurophysiological stigmata of brain retraction injury can be identified, with the operation simultaneous recorded with the operative microscope.

    Time frame: Over a 28 month period from November 2022 to March 2026

06

Study locations

1 of 1 sites recruiting
  • National Hospital Neurology and Neurosurgery
    London, Greater London WC1N 3BG, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06409806
Lead sponsor
University College, London
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Aug 1, 2022
Primary completion
Dec 1, 2024 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Siddharth Sinha
Contact
siddharth.sinha@ucl.ac.uk
004420 3456 7890

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion